RCS, that's what I am wondering. I am beginning to think that benign tissue plays a larger role in post treatment patients than may be realized. There's a study out this week, in the newspaper, where they used Avodart for pre-treatment men to drive the psa down, and then they could get a baseline of when there was actual cancer forming, since the psa had been forced down but then began to rise. Supposedly will give a better feel for when to begin more aggressive testing and biopsy. They even was able to do some early correlation on aggressiveness. In this months online Journal of Urology.
It'd be good to have a drug that could reliabily force 'good' benign prostate tissue psa down and keep it down, then when a real PCa reoccurarance starts you would know which was which. Those .04's to .19's would be able to plan better, wouldn't they? Like I said, I suspect there's more to benign tissue psa after treatments than we understand now.
James C. Age 63
Gonna Make Myself A Better Man tinyurl.com/28e8qcg
4/07: PSA 7.6, 7/07 Biopsy: 3 of 16 PCa, 5% involved, left lobe, GS6
9/07: Nerve Sparing
open RP, Path: pT2c, 110 gms., clear except:
Probable microscopic involvement-left apical margin -GS6
3 Years: PSA's .04 each test until 04/10-.06, 09/10-.09, 01/11-.09